drugset
drugset / Trial / NCT04813471

Managing Endothelial Dysfunction in Critically Ill COVID-19 Patients at LAUMCRH

NCT04813471 ↗

Phase 3 Unknown 70 enrolled Lebanese American University Medical Center
RandomizedParallel-groupOpen-labelTreatment

Summary

COVID-19 Infection has been found to cause endothelial dysfunction and most of the adverse events stem to this mechanism. So we seek to target endothelial dysfunction in critically Ill patients with covid by giving them an endothelial protocol ( L-arginine, Folic Acid, Statin, Nicorandil, Vitamin B complex) and monitor clinical outcome in those patients.

Timeline

Start
2021-01-20
Primary completion
2021-03-20
Completion
2021-04-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Atorvastatin Small molecule 40 mg Oral
Subject L-arginine Small molecule 1 g Oral
Subject Nicorandil Other / unclassified 20 mg Oral
Subject Vitamin B Complex Unknown 1 unknown Intravenous
Subject folic acid Other / unclassified 5 mg Oral

Indications

COVID-19